-
Electronic (PDF)
-
Site License
-
Enterprisewide
Cervical Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018
GlobalData, December 2011, Pages: 128
Cervical Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Cervical Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Cervical Cancer Therapeutics market. The report identifies the key trends shaping and driving the global Cervical Cancer Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Cervical Cancer Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Cervical Cancer Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Cervical Cancer Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Cervical Cancer Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Cervical Cancer Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Cervical Cancer Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Cervical Cancer Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Cervical Cancer Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Cervical Cancer Therapeutics market landscape? – Identify, understand and capitalize
Keywords
Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials
1
1
1.1 List of Tables
1.2 List of Figures
2 Cervical Cancer - Introduction
2.1 Introduction
2.2 Disease Definition
2.3 Cytology Classification Systems for Cervical Neoplasms
2.4 Epidemiology
2.5 Etiology and Pathophysiology
2.6 Risk Factors for Cervical Cancer
2.7 Symptoms
2.8 Diagnosis
2.8.1 Pap Smear
2.8.2 Colposcopy
2.8.3 Biopsy
2.8.4 Human Papillomavirus Test
2.8.5 Pelvic Exam
2.8.6 Endocervical Curettage
2.8.7 Other Methods of Detecting HPV Infections
2.9 Staging of Cervical Cancer
2.10 Treatment for Patients with Cervical Cancer
2.10.1 Surgery
2.10.2 Radiation Therapy
2.10.3 Chemotherapy
2.11 Treatment by Stage of the Disease
2.12 Cervical Cancer Screening Guidelines in the US
2.13 GlobalData Pipeline Report Guidance
3 Cervical Cancer - Market Characterization
3.1 Cervical Cancer Market Size (2005-2010) - Global
3.2 Cervical Cancer Market Forecast (2010-2018) – Global
3.3 Cervical Cancer Market Size (2005-2010) - The US
3.4 Cervical Cancer Market Forecast (2010-2018) - The US
3.5 Cervical Cancer Market Size (2005-2010) - The UK
3.6 Cervical Cancer Market Forecast (2010-2018) - The UK
3.7 Cervical Cancer Market Size (2005-2010) - Germany
3.8 Cervical Cancer Market Forecast (2010-2018) - Germany
3.9 Cervical Cancer Market Size (2005-2010) - France
3.10 Cervical Cancer Market Forecast (2010-2018) - France
3.11 Cervical Cancer Market Size (2005-2010) - Italy
3.12 Cervical Cancer Market Forecast (2010-2018) - Italy
3.13 Cervical Cancer Market Size (2005-2010) - Spain
3.14 Cervical Cancer Market Forecast (2010-2018) - Spain
3.15 Cervical Cancer Market Size (2005-2010) - Japan
3.16 Cervical Cancer Market Forecast (2010-2018) - Japan
3.17 Drivers and Barriers for the Cervical Cancer Market
3.17.1 Drivers for the Cervical Cancer Market
3.17.2 Barriers for the Cervical Cancer Market
3.18 Opportunity and Unmet Need
3.18.1 Opportunity and Unmet Need for the Cervical Cancer Prophylactics Market
3.18.2 Opportunity and Unmet Need for the Cervical Cancer Therapeutics Market
3.19 Key Takeaway
4 Cervical Cancer Market - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.2.1 Limitations of Current HPV Vaccines
4.2.2 Reimbursement Policy in The US
4.2.3 Competitor Assessment within Different Categories Employed in Cervical Cancer Treatment
4.3 Product Profile for Marketed Drugs and Vaccines in the Cervical Cancer Market
4.3.1 Gardasil (HPV quadrivalent (type 6, 11, 16 and 18) vaccine recombinant)
4.3.2 Cervarix (human papillomavirus bivalent (types 16 and 18))
4.3.3 Hycamtin (topotecan hydrochloride)
4.4 Key Takeaway
5 Cervical Cancer - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Cervical Cancer – Pipeline by Phases of Development
5.3.1 Cervical Cancer – Phase III Pipeline
5.3.2 Cervical Cancer – Phase II Pipeline
5.3.3 Cervical Cancer – Phase I/II Pipeline
5.3.4 Cervical Cancer – Phase I Pipeline
5.3.5 Cervical Cancer – Preclinical Pipeline
5.3.6 Cervical Cancer – Discovery Pipeline
5.4 Cervical Cancer– Pipeline by Mechanism of Action
5.5 Cervical Cancer – Pipeline by Treatment Approach
5.5.1 Technology Trends Analytic Framework
5.6 Cervical Cancer – Promising Drugs under Clinical Development
5.7 Molecule Profile for Promising Drugs under Clinical Development
5.7.1 V503
5.7.2 S-1 (in combination with cisplatin)
5.7.3 Z-100 (with radiation)
5.8 Challenges in the Development of Cervical Cancer Vaccines
5.8.1 Deficit of Animal Models for HPV
5.8.2 Poor Understanding of Immune Response to HPV
5.8.3 Effective Prevention can be Achieve with a Multivalent Vaccine
5.8.4 Limited Knowledge of the Mucosal Immune Response
5.9 Key Takeaway
6 Cervical Cancer - Clinical Trials Mapping
6.1 Clinical Trials by Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Status
6.4 Overall Sponsors
6.5 Prominent Sponsors
6.6 Top Companies Participating in Cervical Cancer Clinical Trials
7 Cervical Cancer - Strategic Assessment
7.1 Cervical Cancer Therapeutics: Implications for Future Market Competition
8 Cervical Cancer - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Merck & Co., Inc. (Merck).
8.2.2 Sanofi Pasteur MSD (Subsidiary of Merck & Co., Inc.)
8.2.3 GlaxoSmithKline plc (GSK)
8.2.4 Zeria Pharmceutical Co., Ltd. (Zeria)
8.2.5 Taiho Pharmaceutical Co., Ltd. (Subsidiary of Otsuka Holdings Co., Ltd.)
8.2.6 Other Companies in the Cervical Cancer Market
9 Cervical Cancer: Licensing and Partnership Deals
10 Cervical Cancer Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography
1.1 List of Tables
Table 1: Cervical Cancer, Incidence and Mortality Cases in 2010
Table 2: Cervical Cancer Staging – TNM and FIGO, 2011
Table 3: Comparison of Cervarix and Gardasil
Table 4: Cervical Cancer Screening Guidelines in the US
Table 5: Recommendations# and Funding Status for HPV Vaccines in EU5 as of November 01, 2007
Table 6: Cervical Cancer Market, Global, Revenue ($m), 2005–2010
Table 7: Cervical Cancer Market, Global, Forecast ($m), 2010–2018
Table 8: Cervical Cancer Market, The US, Revenue ($m), 2005–2010
Table 9: Cervical Cancer Market, The US, Forecast ($m), 2010–2018
Table 10: Cervical Cancer Market, The UK, Revenue ($m), 2005–2010
Table 11: Cervical Cancer Market, The UK, Forecast ($m), 2010–2018
Table 12: Cervical Cancer Market, Germany, Revenue ($m), 2005–2010
Table 13: Cervical Cancer Market, Germany, Forecast ($m), 2010–2018
Table 14: Cervical Cancer Market, France, Revenue ($m), 2005–2010
Table 15: Cervical Cancer Market, France, Forecast ($m), 2010–2018
Table 16: Cervical Cancer Market, Italy, Revenue ($m), 2005–2010
Table 17: Cervical Cancer Market, Italy, Forecast ($m), 2010–2018
Table 18: Cervical Cancer Market, Spain, Revenue ($m), 2005–2010
Table 19: Cervical Cancer Market, Spain, Forecast ($m), 2010–2018
Table 20: Cervical Cancer Market, Japan, Revenue ($m), 2005–2010
Table 21: Cervical Cancer Market, Japan, Forecast ($m), 2010–2018
Table 22: Description of Prophylactic Cervical Cancer Vaccines
Table 23: Gardasil Approvals and Fillings
Table 24: Major Marketed Drugs and Vaccines Comparison in the Cervical Cancer Market, 2011
Table 25: Cervical Cancer – Phase III Pipeline, 2011
Table 26: Cervical Cancer – Phase II Pipeline, 2011
Table 27: Cervical Cancer – Phase I/II Pipeline, 2011
Table 28: Cervical Cancer – Phase I Pipeline, 2011
Table 29: Cervical Cancer – Preclinical Pipeline, 2011
Table 30: Cervical Cancer – Discovery Pipeline, 2011
Table 31: Mechanism of Action for the ‘Other’ Molecules in Figure 68
Table 32: Cervical Cancer– Promising Drugs Under Clinical Development, 2011
Table 33: Cervical Cancer – Clinical Trials by Country, 2011
Table 34: Cervical Cancer – Clinical Trials by Phase, 2011
Table 35: Cervical Cancer – Clinical Trials by Status, 2011
Table 36: Cervical Cancer – Overall Sponsors, 2011
Table 37: Cervical Cancer – Prominent Sponsors, 2011
Table 38: Cervical Cancer: Top Companies Participating in Clinical Trials, 2011
Table 39: Cervical Cancer Market – Other Future Players, 2011
Table 40: Cervical Cancer, Licensing and Partnership Deals, 2011
1.2 List of Figures
Figure 1: Comparison of Cytology Classification Systems for Cervical Neoplasms
Figure 2: Cervical Cancer, Incidence and Mortality Cases in 2010
Figure 3: Human Papillomavirus Infection and Replication in Cervical Epithelial Cells
Figure 4: Clinical Pathology of Cervical Cancer
Figure 5: Pap Smear Test
Figure 6: Pelvic Exam
Figure 7: Stages of Cervical Cancer
Figure 8: Chemotherapy Regimens for Recurrent or Metastatic Cervical Cancer
Figure 9: Cervical Cancer Treatment by Stage of Disease, 2011
Figure 10: Cervical Cancer Treatment and Dosage - Chemo-radiation Therapy or Chemotherapy by Stage, 2011
Figure 11: Cervical Cancer Prophylactics Market, Global, Revenue ($m), 2006-2010
Figure 12: Cervical Cancer Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 13: Cervical Cancer, Global, Market Share (%), 2010
Figure 14: Cervical Cancer Prophylactics Market, Global, Forecasts ($m), 2010-2018
Figure 15: Cervical Cancer Therapeutics Market, Global, Forecasts ($m), 2010-2018
Figure 16: Cervical Cancer, Global, Market Share (%), 2018
Figure 17: Cervical Cancer Prophylactics Market, The US, Revenue ($m), 2006-2010
Figure 18: Cervical Cancer Therapeutics Market, The US, Revenue ($m), 2005-2010
Figure 19: Cervical Cancer, The US, Market Share (%), 2010
Figure 20: Cervical Cancer Prophylactics Market, The US, Forecasts ($m), 2010-2018
Figure 21: Cervical Cancer Therapeutics Market, The US, Forecasts ($m), 2010-2018
Figure 22: Cervical Cancer, The US, Market Share (%), 2018
Figure 23: Cervical Cancer Prophylactics Market, The UK, Revenue ($m), 2007-2010
Figure 24: Cervical Cancer Therapeutics Market, The UK, Revenue ($m), 2005-2010
Figure 25: Cervical Cancer, The UK, Market Share (%), 2010
Figure 26: Cervical Cancer Prophylactics Market, The UK, Forecast ($m), 2010-2018
Figure 27: Cervical Cancer Therapeutics Market, The UK, Forecast ($m), 2010-2018
Figure 28: Cervical Cancer, The UK, Market Share (%), 2018
Figure 29: Cervical Cancer Prophylactics Market, Germany, Revenue ($m), 2007-2010
Figure 30: Cervical Cancer Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 31: Cervical Cancer, Germany, Market Share (%), 2010
Figure 32: Cervical Cancer Prophylactics Market, Germany, Forecast ($m), 2010-2018
Figure 33: Cervical Cancer Therapeutics Market, Germany, Forecast ($m), 2010-2018
Figure 34: Cervical Cancer, Germany, Market Share (%), 2018
Figure 35: Cervical Cancer Prophylactics Market, France, Revenue ($m), 2007-2010
Figure 36: Cervical Cancer Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 37: Cervical Cancer, France, Market Share (%), 2010
Figure 38: Cervical Cancer Prophylactics Market, France, Forecast ($m), 2010-2018
Figure 39: Cervical Cancer Therapeutics Market, France, Forecast ($m), 2010-2018
Figure 40: Cervical Cancer, France, Market Share (%), 2018
Figure 41: Cervical Cancer Prophylactics Market, Italy, Revenue ($m), 2007-2010
Figure 42: Cervical Cancer Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 43: Cervical Cancer, Italy, Market Share (%), 2010
Figure 44: Cervical Cancer Prophylactics Market, Italy, Forecast ($m), 2010-2018
Figure 45: Cervical Cancer Prophylactics Market, Italy, Forecast ($m), 2010-2018
Figure 46: Cervical Cancer, Italy, Market Share (%), 2018
Figure 47: Cervical Cancer Prophylactics Market, Spain, Revenue ($m), 2007-2010
Figure 48: Cervical Cancer Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 49: Cervical Cancer, Spain, Market Share (%), 2010
Figure 50: Cervical Cancer Prophylactics Market, Spain, Forecast ($m), 2010-2018
Figure 51: Cervical Cancer Therapeutics Market, Spain, Forecast ($m), 2010-2018
Figure 52: Cervical Cancer, Spain, Market Share (%), 2018
Figure 53: Cervical Cancer Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 54: Cervical Cancer, Japan, Market Share (%), 2010
Figure 55: Cervical Cancer Prophylactics Market, Japan, Forecast ($m), 2010-2018
Figure 56: Cervical Cancer Therapeutics Market, Japan, Forecast ($m), 2010-2018
Figure 57: Cervical Cancer, Japan, Market Share (%), 2018
Figure 58: Cervical Cancer Market, Drivers and Barriers, 2011
Figure 59: Cervical Cancer Market, Drivers and Barriers and its Influence, 2011
Figure 60: Opportunity and Unmet Need for Cervical Cancer Prophylactics Market, 2011
Figure 61: Opportunity and Unmet Need for Cervical Cancer Therapeutics Market, 2011
Figure 62: Implementation and Financing Policy in The US
Figure 63: Cervical Cancer Prophylactics Market – Strategic Competitor Assessment, 2011
Figure 64: Cervical Cancer Therapeutics Market – Strategic Competitor Assessment, 2011
Figure 65: Cervical Cancer – Pipeline by Phase of Development, 2011
Figure 66: Cervical Cancer – Clinical Pipeline by Mechanism of Action, 2011
Figure 67: Overall Cervical Cancer – Clinical Pipeline by Treatment Type, 2011
Figure 68: Cervical Cancer – Clinical Pipeline Comparing Treatment Types, 2011
Figure 69: Cervical Cancer – Technology Trends Analytics Framework, 2011
Figure 70: Cervical Cancer – Clinical Trials by Country, 2011
Figure 71: Cervical Cancer – Clinical Trials by Phase, 2011
Figure 72: Cervical Cancer – Clinical Trials by Status, 2011
Figure 73: Cervical Cancer – Overall Sponsors, 2011
Figure 74: Cervical Cancer – Prominent Sponsors, 2011
Figure 75: Cervical Cancer – Prominent Sponsors, 2011
Figure 76: Implications for Future Market Competition in Cervical Cancer Prophylactics Market, 2011
Figure 77: Implications for Future Market Competition in Cervical Cancer Therapeutics Market, 2011
Figure 78: GlobalData Market Forecasting Model
GlobalData, the industry analysis specialist, has released its new report, “Cervical Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Cervical Cancer Therapeutics market. The report identifies the key trends shaping and driving the global Cervical Cancer Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Cervical Cancer Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
The Cervical Cancer Market is Forecast to Show Slow Growth until 2018
GlobalData estimates that the global cervical cancer market was worth $1,793.3m in 2010, after increasing at a Compound Annual Growth Rate (CAGR) of 62.7% during 2006–2010. During 2010–2018, the market is expected to record a CAGR of 3.6%, from $1,793.3m in 2010 to $2,377.3m in 2018.
The overall cervical cancer market consists of the cervical cancer prophylactics market and the cervical cancer therapeutics market. The cervical cancer prophylactics market grew at a CAGR of 61.5% from $234.8m in 2006 to $1,598.7m in 2010. The cervical cancer therapeutics market grew at a CAGR of 4.3% from $157.3m in 2005 to $194.5m in 2010.
The prophylactics market experienced significant growth in the historic period due to the launch of Gardasil (Human Papillomavirus (HPV) quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant) and Cervarix (HPV bivalent (types 16 and 18) vaccine, recombinant). Gardasil was approved in the US and Europe in 2006 and in Japan in 2011. Similarly, Cervarix was approved in Europe in 2007 and in the US and Japan in 2009. The prophylactics market is expected to grow in the forecast period to 2018 due to the expected launch of the First-In-Class (FIC) vaccine, V503 in 2013, although growth will be slow.
Growth in the cervical cancer therapeutics market is expected to decline in the forecast period until 2018, primarily due to the generic erosion of Hycamtin, the only approved therapeutic treatment option available in the market for advanced and recurrent cervical cancer patients. Its patent expired in the US in 2010 and will expire in Europe in 2011. In Japan, the therapeutics market is expected to show steady growth during the forecast period, attributed to the expected launch of two upcoming FIC molecules.
Cervical Cancer Market, Global, Revenue and Forecasts ($m), 2005-2018
Sources: GlobalData, GLOBOCAN 2008, National Comprehensive Cancer Network (NCCN) Treatment Guidelines, Preparing for the Introduction of HPV Vaccine in the WHO European Region, World Health Organization 2008, The European Association for Palliative Care (EAPC), European Cervical Cancer Association (ECCA), The United States Food and Drug Administration (FDA), The United States Patent and Trademark Office (USPTO), European Medicine Agency (EMEA), GlobalData Epidemiology-based Market Forecasting Model, Primary Research Interviews, Company Annual Reports.
Merck & Co., Inc. (Merck).
Sanofi Pasteur MSD (Subsidiary of Merck & Co., Inc.)
GlaxoSmithKline plc (GSK)
Zeria Pharmceutical Co., Ltd. (Zeria)
Taiho Pharmaceutical Co., Ltd. (Subsidiary of Otsuka Holdings Co., Ltd.)
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
